REGENXBIO (NASDAQ:RGNX) Sets New 1-Year Low at $10.44

Shares of REGENXBIO Inc. (NASDAQ:RGNX) reached a new 52-week low on Monday . The company traded as low as $10.44 and last traded at $10.47, with a volume of 149589 shares. The stock had previously closed at $10.80.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price target on shares of REGENXBIO in a research note on Wednesday, September 4th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. The Goldman Sachs Group assumed coverage on REGENXBIO in a research note on Friday, June 7th. They set a “buy” rating and a $38.00 price target on the stock. Finally, Barclays dropped their price target on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $37.91.

REGENXBIO Stock Down 5.3 %

The company has a market capitalization of $505.57 million, a PE ratio of -1.84 and a beta of 1.22. The stock has a 50-day moving average of $12.32 and a 200 day moving average of $14.53.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.24. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. The business had revenue of $22.30 million during the quarter, compared to the consensus estimate of $22.97 million. During the same period last year, the business posted ($1.66) earnings per share. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Equities analysts forecast that REGENXBIO Inc. will post -4.66 EPS for the current fiscal year.

Insider Activity at REGENXBIO

In other REGENXBIO news, Director Kenneth T. Mills sold 2,210 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $13.77, for a total transaction of $30,431.70. Following the completion of the transaction, the director now owns 408,035 shares in the company, valued at $5,618,641.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.56, for a total transaction of $115,600.00. Following the completion of the sale, the director now owns 11,286 shares of the company’s stock, valued at $130,466.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Kenneth T. Mills sold 2,210 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $13.77, for a total transaction of $30,431.70. Following the completion of the transaction, the director now owns 408,035 shares in the company, valued at approximately $5,618,641.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,279 shares of company stock worth $762,934. Company insiders own 13.13% of the company’s stock.

Institutional Investors Weigh In On REGENXBIO

Institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its stake in shares of REGENXBIO by 73.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 746 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in REGENXBIO during the 1st quarter valued at about $56,000. Headlands Technologies LLC increased its holdings in REGENXBIO by 276.8% during the 1st quarter. Headlands Technologies LLC now owns 3,828 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 2,812 shares during the period. Diversified Trust Co bought a new position in REGENXBIO during the 2nd quarter valued at approximately $121,000. Finally, Arizona State Retirement System lifted its holdings in REGENXBIO by 20.6% in the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock worth $137,000 after buying an additional 1,997 shares during the period. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.